Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Ableson tyrosine kinase (ABL) is crucial for cellular functions, but its fusion with BCR drives chronic myelogenous leukemia (CML).
• Tyrosine kinase inhibitors (TKIs) like imatinib have been effective against CML, yet resistance necessitates new therapeutic strategies.
• Identifying direct ABL kinase substrates is vital for understanding its role in cancer and discovering novel drug targets.

Purpose of the Study:

• To present a refined proteomic approach, kinase assay linked phosphoproteomics (KALIP), for identifying direct kinase substrates.
• To elucidate direct substrates of ABL, particularly in the context of TKI treatment and resistance.
• To discover novel drug targets for CML and potentially other cancers with dysregulated kinase signaling.

Main Methods:

• Integration of in vitro kinase assays (peptide and protein levels) with quantitative tyrosine phosphoproteomics.
• Utilizing multiple TKIs to mitigate off-target drug effects and refine substrate identification.
• Cross-referencing in vivo and in vitro data to establish a high-confidence list of direct kinase substrates.

Main Results:

• The KALIP approach identified a list of 60 direct ABL substrates, encompassing both known and novel proteins.
• Spleen tyrosine kinase (SYK) was confirmed as a novel direct substrate of ABL.
• The study provides a robust methodology for substrate identification in kinase-driven signaling pathways.

Conclusions:

• The KALIP method is effective for identifying direct kinase substrates, advancing our understanding of ABL signaling.
• The identification of novel substrates like SYK opens avenues for developing new therapeutic strategies against CML.
• This proteomic strategy holds promise for discovering kinase substrates in other cancers characterized by aberrant kinase activity.